Geodesic
Modeling the differential effect of \emph{CYP2C9} gene alleles on losartan metabolism
Matematičeskaâ biologiâ i bioinformatika, Tome 19 (2024), pp. 533-564.

Voir la notice de l'article provenant de la source Math-Net.Ru

Arterial hypertension is a multifactorial disease characterized by an increase in systolic and/or diastolic blood pressure. This pathology affects about a billion people worldwide. Hypertension is also a common risk factor for the development of different cardiovascular diseases, which are the leading cause of death in the population, claiming about 17 million lives annually. Various antihypertensive drugs are used to control hypertension, for example, losartan, a selective angiotensin II AT1-receptor antagonist. Losartan is primarily metabolized in the liver by CYP2C9, a member of the cytochrome P450 superfamily, to the pharmacologically active metabolite carboxylosartan (E-3174). The CYP2C9 gene is highly polymorphic: numerous single nucleotide polymorphisms that alter the function of the enzyme have been described in the literature. The most widespread CYP2C9 alleles are CYP2C9*1 (wild-type), CYP2C9*2 and CYP2C9*3. Here, we performed mathematical modeling of the metabolism of orally administered losartan to E-3174, taking into account combinations of the most common CYP2C9 alleles. It was shown that, depending on the CYP2C9 genotype, the pharmacokinetics of losartan and E-3174 differ significantly, which is confirmed by previously published experimental data. To develop and analyze the model, we used the BioUML software. The results of the modeling can potentially be used to personalize drug therapy for arterial hypertension. 
@article{MBB_2024_19_a21,
     author = {D. S. Babaev and E. O. Kutumova and F. A. Kolpakov},
     title = {Modeling the differential effect of {\emph{CYP2C9}} gene alleles on losartan metabolism},
     journal = {Matemati\v{c}eska\^a biologi\^a i bioinformatika},
     pages = {533--564},
     publisher = {mathdoc},
     volume = {19},
     year = {2024},
     language = {ru},
     url = {http://geodesic.mathdoc.fr/item/MBB_2024_19_a21/}
}
TY  - JOUR
AU  - D. S. Babaev
AU  - E. O. Kutumova
AU  - F. A. Kolpakov
TI  - Modeling the differential effect of \emph{CYP2C9} gene alleles on losartan metabolism
JO  - Matematičeskaâ biologiâ i bioinformatika
PY  - 2024
SP  - 533
EP  - 564
VL  - 19
PB  - mathdoc
UR  - http://geodesic.mathdoc.fr/item/MBB_2024_19_a21/
LA  - ru
ID  - MBB_2024_19_a21
ER  - 
%0 Journal Article
%A D. S. Babaev
%A E. O. Kutumova
%A F. A. Kolpakov
%T Modeling the differential effect of \emph{CYP2C9} gene alleles on losartan metabolism
%J Matematičeskaâ biologiâ i bioinformatika
%D 2024
%P 533-564
%V 19
%I mathdoc
%U http://geodesic.mathdoc.fr/item/MBB_2024_19_a21/
%G ru
%F MBB_2024_19_a21
D. S. Babaev; E. O. Kutumova; F. A. Kolpakov. Modeling the differential effect of \emph{CYP2C9} gene alleles on losartan metabolism. Matematičeskaâ biologiâ i bioinformatika, Tome 19 (2024), pp. 533-564. http://geodesic.mathdoc.fr/item/MBB_2024_19_a21/

[1] D. R. Nelson, “Cytochrome P450 nomenclature, 2004”, Cytochrome P450 Protocols, Methods in Molecular Biology, 320, eds. Phillips I. R., E. A. Shephard, Humana Press, Totowa, NJ, 2006, 1–10 <ext-link ext-link-type='doi' href='https://doi.org/10.1385/1-59259-998-2:1'>10.1385/1-59259-998-2:1</ext-link>

[2] D. W. Nebert, D. W. Russell, “Clinical importance of the cytochromes P450”, The Lancet, 360 (2002), 1155–1162 <ext-link ext-link-type='doi' href='https://doi.org/10.1016/S0140-6736(02)11203-7'>10.1016/S0140-6736(02)11203-7</ext-link>

[3] H. Takahashi, H. Echizen, “Pharmacogenetics of warfarin elimination and its clinical implications”, Clin. Pharmacokinet, 40 (2001), 587–603 <ext-link ext-link-type='doi' href='https://doi.org/10.2165/00003088 200140080-00003'>10.2165/00003088 200140080-00003</ext-link>

[4] U. M. Zanger, M. Turpeinen, K. Klein, M. Schwab, “Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation”, Anal. Bioanal. Chem, 392 (2008), 1093–1108 <ext-link ext-link-type='doi' href='https://doi.org/10.1007/s00216-008-2291-6'>10.1007/s00216-008-2291-6</ext-link>

[5] U. M. Zanger, M. Schwab, “Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation”, Pharmacol. Ther, 138 (2013), 103–141 <ext-link ext-link-type='doi' href='https://doi.org/10.1016/j.pharmthera.2012.12.007'>10.1016/j.pharmthera.2012.12.007</ext-link>

[6] J. O. Miners, D. J. Birkett, “Cytochrome P4502C9: an enzyme of major importance in human drug metabolism”, Br. J. Clin. Pharmacol, 45 (1998), 525–538 <ext-link ext-link-type='doi' href='https://doi.org/10.1046/j.1365-2125.1998.00721.x'>10.1046/j.1365-2125.1998.00721.x</ext-link>

[7] I. C. Gray, C. Nobile, R. Muresu, S. Ford, N. K. Spurr, “A 2,4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24”, Genomics, 28 (1995), 328–332 <ext-link ext-link-type='doi' href='https://doi.org/10.1006/geno.1995.1149'>10.1006/geno.1995.1149</ext-link>

[8] C. R. Lee, J. A. Goldstein, J. A. Pieper, “Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data”, Pharmacogenetics, 12 (2002), 251–263 <ext-link ext-link-type='doi' href='https://doi.org/10.1097/00008571-200204000-00010'>10.1097/00008571-200204000-00010</ext-link>

[9] C. Ged, D. R. Umbenhauer, T. M. Bellew, R. W. Bork, P. K. Srivastava, N. Shinriki, R. S. Lloyd, F. P. Guengerich, “Characterization of cDNAs, mRNAs, and proteins related to human liver microsomal cytochrome P-450 (S)-mephenytoin 4'-hydroxylase”, Biochemistry, 27 (1988), 6929–6940 <ext-link ext-link-type='doi' href='https://doi.org/10.1021/bi00418a039'>10.1021/bi00418a039</ext-link>

[10] M. J. Stubbins, L. W. Harries, G. Smith, M. H. Tarbit, C. R. Wolf, “Genetic analysis of the human cytochrome P450 CYP2C9 locus”, Pharmacogenetics, 6 (1996), 429–439 <ext-link ext-link-type='doi' href='https://doi.org/10.1097/00008571-199610000-00007'>10.1097/00008571-199610000-00007</ext-link>

[11] T. H. Sullivan-Klose, B. I. Ghanayem, D. A. Bell, Z. Y. Zhang, L. S. Kaminsky, G. M. Shenfield, J. O. Miners, D. J. Birkett, J. A. Goldstein, “The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism”, Pharmacogenetics, 6 (1996), 341–349 <ext-link ext-link-type='doi' href='https://doi.org/10.1097/00008571-199608000-00007'>10.1097/00008571-199608000-00007</ext-link>

[12] U. I. Schwarz, “Clinical relevance of genetic polymorphisms in the human CYP2C9 gene”, Eur. J. Clin. Invest., 33, Suppl. 2 (2003), 23–30 <ext-link ext-link-type='doi' href='https://doi.org/10.1046/j.1365-2362.33.s2.6.x'>10.1046/j.1365-2362.33.s2.6.x</ext-link>

[13] D. Si, Y. Guo, Y. Zhang, L. Yang, H. Zhou, D. Zhong, “Identification of a novel variant CYP2C9 allele in Chinese”, Pharmacogenetics, 14 (2004), 465–469 <ext-link ext-link-type='doi' href='https://doi.org/10.1097/01.fpc.0000114749.08559.e4'>10.1097/01.fpc.0000114749.08559.e4</ext-link>

[14] J. B. McCrea, A. Cribb, T. Rushmore, B. Osborne, L. Gillen, M. W. Lo, S. Waldman, T. Bjornsson, S. Spielberg, M. R. Goldberg, “Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174”, Clin. Pharmacol. Ther, 65 (1999), 348–352 <ext-link ext-link-type='doi' href='https://doi.org/10.1016/S0009-9236(99)70114-1'>10.1016/S0009-9236(99)70114-1</ext-link>

[15] R. A. Stearns, P. K. Chakravarty, R. Chen, S. H. Chiu, “Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and subfamily members”, Drug Metab. Dispos, 23 (1995), 207–215, 3 pp.

[16] K. M. Kaukonen, K. T. Olkkola, P. J. Neuvonen, “Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174”, Eur. J. Clin. Pharmacol, 53 (1998), 445–449 <ext-link ext-link-type='doi' href='https://doi.org/10.1007/s002280050405'>10.1007/s002280050405</ext-link>

[17] K. M. Williamson, J. H. Patterson, R. H. McQueen, K. F.J. Adams, J. A. Pieper, “Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers”, Clin. Pharmacol. Ther, 63 (1998), 316–323 <ext-link ext-link-type='doi' href='https://doi.org/10.1016/S0009-9236(98)90163-1'>10.1016/S0009-9236(98)90163-1</ext-link>

[18] M. R. Goldberg, M. W. Lo, T. E. Bradstreet, M. A. Ritter, P. Hoglund, “Effects of cimetidine on pharmacokinetics and pharmacodynamics of losartan, an AT1-selective non-peptide angiotensin II receptor antagonist”, Eur. J. Clin. Pharmacol, 49 (1995), 115–119 <ext-link ext-link-type='doi' href='https://doi.org/10.1007/BF00192369'>10.1007/BF00192369</ext-link>

[19] M. Kobayashi, M. Takagi, K. Fukumoto, R. Kato, K. Tanaka, K. Ueno, “The effect of bucolome, a CYP2C9 inhibitor, on the pharmacokinetics of losartan”, Drug Metab. Pharmacokinet, 23 (2008), 115–119 <ext-link ext-link-type='doi' href='https://doi.org/10.2133/dmpk.23.115'>10.2133/dmpk.23.115</ext-link>

[20] A. Wennerholm, A. Nordmark, M. Pihlsgard, M. Mahindi, L. Bertilsson, Gustafsson L. L. Amodiaquine, “its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo”, Eur. J. Clin. Pharmacol, 62 (2006), 539–546 <ext-link ext-link-type='doi' href='https://doi.org/10.1007/s00228-006-0121-3'>10.1007/s00228-006-0121-3</ext-link>

[21] P. B. Timmermans, P. C. Wong, A. T. Chiu, W. F. Herblin, P. Benfield, D. J. Carini, R. J. Lee, R. R. Wexler, J. A. Saye, R. D. Smith, “Angiotensin II receptors and angiotensin II receptor antagonists”, Pharmacol. Rev, 45 (1993), 205–251

[22] U. Yasar, G. Tybring, M. Hidestrand, M. Oscarson, M. Ingelman-Sundberg, M. L. Dahl, E. Eliasson, “Role of CYP2C9 polymorphism in losartan oxidation”, Drug Metab. Dispos, 29 (2001), 1051–1056

[23] C. H. Yun, H. S. Lee, H. Lee, J. K. Rho, H. G. Jeong, F. P. Guengerich, “Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174”, Drug Metab. Dispos, 23 (1995), 285–289

[24] M. W. Lo, M. R. Goldberg, J. B. McCrea, H. Lu, C. I. Furtek, T. D. Bjornsson, “Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans”, Clin. Pharmacol. Ther, 58 (1995), 641–649 <ext-link ext-link-type='doi' href='https://doi.org/10.1016/0009-9236(95)90020-9'>10.1016/0009-9236(95)90020-9</ext-link>

[25] Yasar U., Forslund-Bergengren C., Tybring G., Dorado P., Llerena A., Sjoqvist F., Eliasson E., Dahl M.L., “Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype”, Clin. Pharmacol. Ther, 71 (2002), 89–98 <ext-link ext-link-type='doi' href='https://doi.org/10.1067/mcp.2002.121216'>10.1067/mcp.2002.121216</ext-link>

[26] E. Karatza, V. Karalis, “Modelling gastric emptying: A pharmacokinetic model simultaneously describing distribution of losartan and its active metabolite EXP-3174”, Basic Clin. Pharmacol. Toxicol, 126 (2020), 193–202 <ext-link ext-link-type='doi' href='https://doi.org/10.1111/bcpt.13321'>10.1111/bcpt.13321</ext-link>

[27] F. Kolpakov, I. Akberdin, T. Kashapov, l. Kiselev, S. Kolmykov, Y. Kondrakhin, E. Kutumova, N. Mandrik, S. Pintus, A. Ryabova et al, “BioUML: an integrated environment for systems biology and collaborative analysis of biomedical data”, Nucleic Acids Res., 47 (2019), W225-W233 <ext-link ext-link-type='doi' href='https://doi.org/10.1093/nar/gkz440'>10.1093/nar/gkz440</ext-link>

[28] F. Kolpakov, I. Akberdin, I. Kiselev, S. Kolmykov, Y. Kondrakhin, M. Kulyashov, E. Kutumova, S. Pintus, A. Ryabova, R. Sharipov et al, “BioUML-towards a universal research platform”, Nucleic Acids Res., 50 (2022), W124-W131 <ext-link ext-link-type='doi' href='https://doi.org/10.1093/nar/gkac286'>10.1093/nar/gkac286</ext-link>

[29] I. N. Kiselev, B. V. Semisalov, E. A. Biberdorf, R. N. Sharipov, A. M. Blokhin, F. A. Kolpakov, “Modulnoe modelirovanie serdechno-sosudistoi sistemy cheloveka”, Matematicheskaya biologiya i bioinformatika, 7:2 (2012), 703–736 <ext-link ext-link-type='doi' href='https://doi.org/10.17537/2012.7.703'>10.17537/2012.7.703</ext-link>

[30] E. O. Kutumova, “Reduktsiya modeli CD95-indutsiruemogo apoptoza”, Matematicheskaya biologiya i bioinformatika, 7:1 (2012), 139–151 <ext-link ext-link-type='doi' href='https://doi.org/10.17537/2012.7.139'>10.17537/2012.7.139</ext-link>

[31] E. O. Kutumova, A. Yu. Zinovev, R. N. Sharipov, F. A. Kolpakov, “Primenenie metodov reduktsii dlya postroeniya kompleksnoi modeli apoptoticheskikh putei”, Matematicheskaya biologiya i bioinformatika, 7:2 (2012), 572–588 <ext-link ext-link-type='doi' href='https://doi.org/10.17537/2012.7.572'>10.17537/2012.7.572</ext-link>

[32] I. N. Kiselev, E. A. Biberdorf, V. I. Baranov, T. G. Komlyagina, V. N. Melnikov, I. Yu. Suvorova, S. G. Krivoschekov, F. A. Kolpakov, “Personalizatsiya parametrov i validatsiya modeli serdechno-sosudistoi sistemy cheloveka”, Matematicheskaya biologiya i bioinformatika, 10:2 (2015), 526–547 <ext-link ext-link-type='doi' href='https://doi.org/10.17537/2015.10.526'>10.17537/2015.10.526</ext-link>

[33] I. N. Kiselev, E. O. Kutumova, A. F. Kolpakova, G. I. Lifshits, F. A. Kolpakov, “Matematicheskoe modelirovanie deistviya antigipertenzivnykh preparatov”, Matematicheskaya biologiya i bioinformatika, 14:1 (2019), 233–256 <ext-link ext-link-type='doi' href='https://doi.org/10.17537/2019.14.233'>10.17537/2019.14.233</ext-link>

[34] I. N. Kiselev, I. R. Akberdin, A. Yu. Vertyshev, D. V. Popov, F. A. Kolpakov, “Modulnaya graficheskaya model energeticheskogo metabolizma v kletkakh skeletnoi myshtsy”, Matematicheskaya biologiya i bioinformatika, 14:2 (2019), 373–392 <ext-link ext-link-type='doi' href='https://doi.org/10.17537/2019.14.373'>10.17537/2019.14.373</ext-link>

[35] I. R. Akberdin, A. Yu. Vertyshev, S. S. Pintus, D. V. Popov, F. A. Kolpakov, “Matematicheskaya model, svyazyvayuschaya Ca2+-zavisimyi signalnyi put s regulyatsiei ekspressii genov v kletkakh skeletnoi myshtsy cheloveka”, Matematicheskaya biologiya i bioinformatika, 15:1 (2020), 20–39 <ext-link ext-link-type='doi' href='https://doi.org/10.17537/2020.15.20'>10.17537/2020.15.20</ext-link>

[36] A. D. Borodulina, E. O. Kutumova, G. I. Lifshits, F. A. Kolpakov, “Matematicheskoe modelirovanie antigipertenzivnoi terapii azilsartana medoksomilom na primere klinicheskikh dannykh realnogo patsienta”, Matematicheskaya biologiya i bioinformatika, 18:1 (2023), 228–250 <ext-link ext-link-type='doi' href='https://doi.org/10.17537/2023.18.228'>10.17537/2023.18.228</ext-link>

[37] P. Yu. Kondrakhin, F. A. Kolpakov, “Mnogourovnevaya matematicheskaya model epilepticheskikh pripadkov”, Matematicheskaya biologiya i bioinformatika, 18:2 (2023), 479–516 <ext-link ext-link-type='doi' href='https://doi.org/10.17537/2023.18.479'>10.17537/2023.18.479</ext-link>

[38] S. M. Keating, D. Waltemath, M. Konig, F. Zhang, A. Drager, C. Chaouiya, F. T. Bergmann, A. Finney, C. S. Gillespie, T. Helikar et al, “SBML Level 3: an extensible format for the exchange and reuse of biological models”, Mol. Syst. Biol., 16 (2020), e9110 <ext-link ext-link-type='doi' href='https://doi.org/10.15252/msb.20199110'>10.15252/msb.20199110</ext-link>

[39] R. S. Malik-Sheriff, M. Glont, T. V.N. Nguyen, K. Tiwari, M. G. Roberts, A. Xavier, M. T. Vu, J. Men, M. Maire, S. Kananathan et al, “BioModels-15 years of sharing computational models in life science”, Nucleic Acids Res., 48 (2020), D407-D415 <ext-link ext-link-type='doi' href='https://doi.org/10.1093/nar/gkz1055'>10.1093/nar/gkz1055</ext-link>

[40] T. Runarsson, X. Yao, “Stochastic ranking for constrained evolutionary optimization”, IEEE Transactions on Evolutionary Computation, 4 (2000), 284–294 <ext-link ext-link-type='doi' href='https://doi.org/10.1109/4235.873238'>10.1109/4235.873238</ext-link>

[41] M. Bjorkman, K. Holmstrom, “Global optimization using the DIRECT algorithm in Matlab”, Adv. Model. Optim., 1 (2004)

[42] S. M. Goldfeld, R. E. Quandt, H. F. Trotter, “Maximization by Quadratic Hill-Climbing”, Econometrica, 34 (1966), 541–551 <ext-link ext-link-type='doi' href='https://doi.org/10.2307/1909768'>10.2307/1909768</ext-link><ext-link ext-link-type='zbl-item-id' href='https://zbmath.org/?q=an:0145.40901'>0145.40901</ext-link>

[43] M. R. Sierra, C. A.C. Coello, “Improving PSO-Based Multi-objective Optimization Using Crowding, Mutation and epsilon-Dominance”, International Conference on Evolutionary Multi-Criterion Optimization, 2005

[44] A. J. Nebro, J. J. Durillo, F. Luna, B. Dorronsoro, E. Alba, “MOCell: A cellular genetic algorithm for multiobjective optimization”, Int. J. Intell. Syst, 24 (2009) <ext-link ext-link-type='zbl-item-id' href='https://zbmath.org/?q=an:1176.90552'>1176.90552</ext-link>

[45] L. Ingber, “Adaptive simulated annealing (ASA): Lessons learned”, Control Cybern, 25 (1996), 33–54 <ext-link ext-link-type='doi' href='https://doi.org/10.48550/arXiv.cs/0001018'>10.48550/arXiv.cs/0001018</ext-link><ext-link ext-link-type='zbl-item-id' href='https://zbmath.org/?q=an:0860.93035'>0860.93035</ext-link>

[46] A. Raue, C. Kreutz, T. Maiwald, J. Bachmann, M. Schilling, U. Klingmuller, J. Timmer, “Structural and practical identifiability analysis of partially observed dynamical models by exploiting the profile likelihood”, Bioinformatics, 25 (2009), 1923–1929 <ext-link ext-link-type='doi' href='https://doi.org/10.1093/bioinformatics/btp358'>10.1093/bioinformatics/btp358</ext-link>

[47] A. Raue, V. Becker, U. Klingmuller, J. Timmer, “Identifiability and observability analysis for experimental design in nonlinear dynamical models”, Chaos Woodbury, 20:2010, 045105 <ext-link ext-link-type='doi' href='https://doi.org/10.1063/1.3528102'>10.1063/1.3528102</ext-link><ext-link ext-link-type='zbl-item-id' href='https://zbmath.org/?q=an:1311.92066'>1311.92066</ext-link>

[48] H. A. Rabitz, M. A. Kramer, D. K. Dacol, “Sensitivity Analysis in Chemical Kinetics”, Annu. Rev. Phys. Chem, 34 (1983), 419–461

[49] P. L. Toutain, A. Bousquet-Melou, “Plasma terminal half-life”, J. Vet. Pharmacol. Ther, 27 (2004), 427–439 <ext-link ext-link-type='doi' href='https://doi.org/10.1111/j.1365-2885.2004.00600.x'>10.1111/j.1365-2885.2004.00600.x</ext-link>

[50] N. Le Novere, M. Hucka, H. Mi, S. Moodie, F. Schreiber, A. Sorokin, E. Demir, K. Wegner, M. I. Aladjem, S. M. Wimalaratne et al, “The Systems Biology Graphical Notation”, Nat. Biotechnol, 27 (2009), 735–741 <ext-link ext-link-type='doi' href='https://doi.org/10.1038/nbt.1558'>10.1038/nbt.1558</ext-link>

[51] E. Deloose, P. Janssen, I. Depoortere, J. Tack, “The migrating motor complex: control mechanisms and its role in health and disease”, Nat. Rev. Gastroenterol. Hepatol, 9 (2012), 271–285 <ext-link ext-link-type='doi' href='https://doi.org/10.1038/nrgastro.2012.57'>10.1038/nrgastro.2012.57</ext-link>

[52] J. Feher, Intestinal and Colonic Chemoreception and Motility, 2017, 796–809 <ext-link ext-link-type='doi' href='https://doi.org/10.1016/B978-0-12-800883-6.00079-3'>10.1016/B978-0-12-800883-6.00079-3</ext-link>

[53] A. F. Dominiczak, D. C. Negrin, J. S. Clark, M. J. Brosnan, M. W. McBride, M. Y. Alexander, “Genes and hypertension: from gene mapping in experimental models to vascular gene transfer strategies”, Hypertens. Dallas Tex., 35 (1979), 164–172 <ext-link ext-link-type='doi' href='https://doi.org/10.1161/01.hyp.35.1.164'>10.1161/01.hyp.35.1.164</ext-link>

[54] C. Menni, M. Mangino, F. Zhang, G. Clement, H. Snieder, S. Padmanabhan, T. D. Spector, “Heritability analyses show visit-to-visit blood pressure variability reflects different pathological phenotypes in younger and older adults: evidence from UK twins”, J. Hypertens, 31 (2013), 2356–2361 <ext-link ext-link-type='doi' href='https://doi.org/10.1097/HJH.0b013e32836523c1'>10.1097/HJH.0b013e32836523c1</ext-link>

[55] H. Chavda, C. Patel, I. S. Anand, “Biopharmaceutics Classification System”, Syst. Rev. Pharm, 1 (2010), 62–69 <ext-link ext-link-type='doi' href='https://doi.org/10.4103/0975-8453.59514'>10.4103/0975-8453.59514</ext-link>

[56] M. Sugihara, S. Takeuchi, M. Sugita, K. Higaki, M. Kataoka, S. Yamashita, “Analysis of Intra- and Intersubject Variability in Oral Drug Absorption in Human Bioequivalence Studies of 113 Generic Products”, Mol. Pharm, 12 (2015), 4405–4413 <ext-link ext-link-type='doi' href='https://doi.org/10.1021/acs.molpharmaceut.5b00602'>10.1021/acs.molpharmaceut.5b00602</ext-link>

[57] Y. Tsume, G. L. Amidon, “The biowaiver extension for BCS class III drugs: the effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation”, Mol. Pharm., 7 (2010), 1235–1243 <ext-link ext-link-type='doi' href='https://doi.org/10.1021/mp100053q'>10.1021/mp100053q</ext-link>

[58] K. Higaki, S. Y. Choe, R. Lobenberg, L. S. Welage, G. L. Amidon, “Mechanistic understanding of time-dependent oral absorption based on gastric motor activity in humans”, Eur. J. Pharm. Biopharm, 70 (2008), 313–325 <ext-link ext-link-type='doi' href='https://doi.org/10.1016/j.ejpb.2008.02.022'>10.1016/j.ejpb.2008.02.022</ext-link>

[59] P. Langguth, K. M. Lee, H. Spahn-Langguth, G. L. Amidon, “Variable gastric emptying and discontinuities in drug absorption profiles: dependence of rates and extent of cimetidine absorption on motility phase and pH”, Biopharm. Drug Dispos, 15 (1994), 719–746 <ext-link ext-link-type='doi' href='https://doi.org/10.1002/bdd.2510150902'>10.1002/bdd.2510150902</ext-link>

[60] R. L. Oberle, G. L. Amidon, “The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon”, J. Pharmacokinet. Biopharm, 15 (1987), 529–544 <ext-link ext-link-type='doi' href='https://doi.org/10.1007/BF01061761'>10.1007/BF01061761</ext-link>

[61] N. Takamatsu, L. S. Welage, Y. Hayashi, R. Yamamoto, J. L. Barnett, V. P. Shah, L. J. Lesko, C. Ramachandran, G. L. Amidon, “Variability in cimetidine absorption and plasma double peaks following oral administration in the fasted state in humans: correlation with antral gastric motility”, Eur. J. Pharm. Biopharm, 53 (2002), 37–47 <ext-link ext-link-type='doi' href='https://doi.org/10.1016/s0939-6411(01)00207-7'>10.1016/s0939-6411(01)00207-7</ext-link>

[62] H. B. Shin, E. H. Jung, P. Kang, C. W. Lim, K. Y. Oh, C. K. Cho, Y. J. Lee, C. I. Choi, C. G. Jang, S. Y. Lee et al, “ABCB1 c2677G>T/c.3435C>T diplotype increases the early-phase oral absorption of losartan”, Arch. Pharm. Res., 43 (2020), 1187–1196 <ext-link ext-link-type='doi' href='https://doi.org/10.1007/s12272-020-01294-3'>10.1007/s12272-020-01294-3</ext-link>